6601 - 6625 of 9039 Results
Title
Year
-
OPENTitle: Protein network analysis links the NSL complex to Parkinson’s disease via mitochondrial and nuclear biologyJournal Name: Molecular OmicsPublisher: Oxford University Press (OUP)Vol: 19Issue #: 8Start Page: 668End Page: 679Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1039/d2mo00325bBest OA location URL: https://pubs.rsc.org/en/content/articlepdf/2023/mo/d2mo00325bCitation Count: 0
- Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarker2022OPENTitle: Global, in situ analysis of the structural proteome in individuals with Parkinson’s disease to identify a new class of biomarkerJournal Name: Nature Structural & Molecular BiologyPublisher: Springer Science and Business Media LLCVol: 29Issue #: 10Start Page: 978End Page: 989Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1038/s41594-022-00837-0Citation Count: 54
- PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum Exposure2021RESTRICTEDTitle: PINK1/Parkin-Mediated Mitophagy Plays a Protective Role in the Bone Impairment Caused by Aluminum ExposureJournal Name: Journal of Agricultural and Food ChemistryPublisher: American Chemical Society (ACS)Vol: 69Issue #: 21Start Page: 6054End Page: 6063Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1021/acs.jafc.1c01921Citation Count: 29
-
OPENTitle: Discovery of Parkinson's disease states and disease progression modelling: a longitudinal data study using machine learningJournal Name: The Lancet Digital HealthPublisher: Elsevier BVVol: 3Issue #: 9Start Page: e555End Page: e564Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/s2589-7500(21)00101-1Best OA location URL: http://www.thelancet.com/article/S2589750021001011/pdfCitation Count: 90
-
OPENTitle: Artificial intelligence for detection of Alzheimer's disease: demonstration of real-world value is required to bridge the translational gapJournal Name: The Lancet Digital HealthPublisher: Elsevier BVVol: 4Issue #: 11Start Page: e768End Page: e769Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/s2589-7500(22)00190-xBest OA location URL: http://www.thelancet.com/article/S258975002200190X/pdfCitation Count: 4
-
OPENTitle: Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and BallismusJournal Name: Canadian Journal of Neurological Sciences / Journal Canadien des Sciences NeurologiquesPublisher: Cambridge University Press (CUP)Vol: 49Issue #: 3Start Page: 431End Page: 432Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1017/cjn.2021.136Citation Count: 3
- Inconsistency and incongruence: the two diagnostic pillars of functional movement disorder2022RESTRICTEDTitle: Inconsistency and incongruence: the two diagnostic pillars of functional movement disorderJournal Name: The LancetPublisher: Elsevier BVVol: 400Issue #: 10348Start Page: 328End Page: 328Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0140-6736(22)01184-9Citation Count: 12
- Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synuclein2022RESTRICTEDTitle: Optimizing the reaction conditions for the GMP production of [18F]ACI-12589, a promising candidate in the development as a PET tracer targeting α-synucleinJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S87End Page: S88Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00207-4Citation Count: 0
- Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursors2022RESTRICTEDTitle: Mild and direct 18F radiofluorination of tetrazines through sulfonium salt precursorsJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 108-109Issue #:Start Page: S88End Page: S89Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s0969-8051(22)00209-8Citation Count: 0
-
OPENTitle: Detection of α-synuclein in CSF by RT-QuIC in patients with isolated rapid-eye-movement sleep behaviour disorder: a longitudinal observational studyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 203End Page: 212Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30449-xBest OA location URL: http://hdl.handle.net/2445/214932Citation Count: 331
-
OPENTitle: Prehospital scales in acute ischaemic stroke management – Authors' replyJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 504End Page: 505Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00169-1Best OA location URL: https://pure.eur.nl/en/publications/25abb6f2-0472-4754-8580-97e2533ac37aCitation Count: 1
- Amantadine in the treatment of Parkinson's disease and other movement disorders2021RESTRICTEDTitle: Amantadine in the treatment of Parkinson's disease and other movement disordersJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 1048End Page: 1056Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00249-0Citation Count: 198
- Freezing of gait and levodopa2021OPENTitle: Freezing of gait and levodopaJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 7Start Page: 505End Page: 506Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00175-7Citation Count: 8
-
OPENTitle: Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 3Start Page: 182End Page: 192Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(20)30489-0Best OA location URL: http://www.thelancet.com/article/S1474442220304890/pdfCitation Count: 137
- The East Asian Parkinson Disease Genomics Consortium2021OPENTitle: The East Asian Parkinson Disease Genomics ConsortiumJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 20Issue #: 12Start Page: 982End Page: 982Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00373-2Citation Count: 9
- Movement disorders research in 2021: cracking the paradigm2021RESTRICTEDTitle: Movement disorders research in 2021: cracking the paradigmJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 1Start Page: 10End Page: 11Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(21)00413-0Citation Count: 19
- Revisiting levodopa for advanced Parkinson's disease2022RESTRICTEDTitle: Revisiting levodopa for advanced Parkinson's diseaseJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1063End Page: 1065Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00435-5Citation Count: 2
- Major advances in Parkinson's disease over the past two decades and future research directions2022RESTRICTEDTitle: Major advances in Parkinson's disease over the past two decades and future research directionsJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1076End Page: 1079Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00448-3Citation Count: 18
- Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trial2022RESTRICTEDTitle: Safety and efficacy of continuous subcutaneous foslevodopa-foscarbidopa in patients with advanced Parkinson's disease: a randomised, double-blind, active-controlled, phase 3 trialJournal Name: The Lancet NeurologyPublisher: Elsevier BVVol: 21Issue #: 12Start Page: 1099End Page: 1109Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/s1474-4422(22)00400-8Citation Count: 204
- Response to: The need of reliable warning signs for dysphagia in Parkinson’s disease: an often-overlooked issue2020RESTRICTEDTitle: Response to: The need of reliable warning signs for dysphagia in Parkinson’s disease: an often-overlooked issueJournal Name: Expert Review of Gastroenterology & HepatologyPublisher: Informa UK LimitedVol: 15Issue #: 3Start Page: 343End Page: 344Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/17474124.2021.1842195Citation Count: 0
- Tablet-based patient educational interventions in care and management of complex movement disorders2021RESTRICTEDTitle: Tablet-based patient educational interventions in care and management of complex movement disordersJournal Name: Disability and Rehabilitation: Assistive TechnologyPublisher: Informa UK LimitedVol: 18Issue #: 5Start Page: 627End Page: 634Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/17483107.2021.1900934Citation Count: 3
- Fast and robust supervised machine learning approach for classification and prediction of Parkinson’s disease onset2021RESTRICTEDTitle: Fast and robust supervised machine learning approach for classification and prediction of Parkinson’s disease onsetJournal Name: Computer Methods in Biomechanics and Biomedical Engineering: Imaging & VisualizationPublisher: Informa UK LimitedVol: 9Issue #: 6Start Page: 690End Page: 706Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1080/21681163.2021.1941262Citation Count: 13
-
OPENTitle: Inhibition of autophagic flux by S-nitrosylation of SQSTM1/p62 promotes neuronal secretion and cell-to-cell transmission of SNCA/α-synuclein in Parkinson disease and Lewy body dementiaJournal Name: Autophagy ReportsPublisher: Informa UK LimitedVol: 1Issue #: 1Start Page: 223End Page: 225Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1080/27694127.2022.2076770Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/27694127.2022.2076770?needAccess=trueCitation Count: 7
-
OPENTitle: Real-world assessment of “OFF” episode–related healthcare resource utilization among patients with Parkinson’s disease in the United StatesJournal Name: Journal of Medical EconomicsPublisher: Informa UK LimitedVol: 24Issue #: 1Start Page: 540End Page: 549Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1080/13696998.2021.1913009Best OA location URL: https://www.tandfonline.com/doi/pdf/10.1080/13696998.2021.1913009?needAccess=trueCitation Count: 9
-
OPENTitle: The impact of COVID-19 on palliative care for people with Parkinson’s and response to future pandemicsJournal Name: Expert Review of NeurotherapeuticsPublisher: Informa UK LimitedVol: 21Issue #: 6Start Page: 615End Page: 623Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1080/14737175.2021.1923480Best OA location URL: http://hdl.handle.net/11577/3395097Citation Count: 16